OBESITY
MCID: OBS005
MIFTS: 92

Obesity (OBESITY) malady

Categories: Genetic diseases, Metabolic diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Obesity

Aliases & Descriptions for Obesity:

Name: Obesity 54 54 38 12 24 66 66 52 41 42 14 69
Obesity, Autosomal Dominant 54 29 13
Obesity, Severe, and Type Ii Diabetes 54 38
Obesity Due to Melanocortin 4 Receptor Deficiency 56
Body Mass Index Quantitative Trait Locus 10 29
Obesity, Mild, Early-Onset 54
Obesity Leanness, Included 54
Obesity, Susceptibility to 29
Obesity, Association with 54
Obesity, Variation in 54
Obesity, Early-Onset 54
Obesity, Late-Onset 54
Obesity, Severe 54
Mc4r Deficiency 56

Characteristics:

Orphanet epidemiological data:

56
obesity due to melanocortin 4 receptor deficiency
Inheritance: Autosomal dominant,Autosomal recessive; Prevalence: 1-5/10000 (France); Age of onset: Infancy,Neonatal;


Classifications:

Orphanet: 56  
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:9970
ICD10 33 E66.9 E66 E66.0
ICD9CM 35 278.00
MeSH 42 D009765
NCIt 47 C3283
Orphanet 56 ORPHA71529
ICD10 via Orphanet 34 E66.8
UMLS 69 C0028754

Summaries for Obesity

MedlinePlus : 41 obesity means having too much body fat. it is different from being overweight, which means weighing too much. the weight may come from muscle, bone, fat, and/or body water. both terms mean that a person's weight is greater than what's considered healthy for his or her height. obesity occurs over time when you eat more calories than you use. the balance between calories-in and calories-out differs for each person. factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active. being obese increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. if you are obese, losing even 5 to 10 percent of your weight can delay or prevent some of these diseases. for example, that means losing 10 to 20 pounds if you weigh 200 pounds. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Obesity, also known as obesity, autosomal dominant, is related to obesity, nr0b2-related and obesity, pparg-related, and has symptoms including hypertension, type ii diabetes mellitus and hypertriglyceridemia. An important gene associated with Obesity is MC4R (Melanocortin 4 Receptor), and among its related pathways/superpathways are Development Ligand-independent activation of ESR1 and ESR2 and Peptide hormone metabolism. The drugs Dexmedetomidine and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include liver, ovary and heart, and related phenotypes are adipose tissue and growth/size/body region

UniProtKB/Swiss-Prot : 66 Obesity: A condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.

Wikipedia : 71 Obesity is a medical condition in which excess body fat has accumulated to the extent that it may have a... more...

Description from OMIM: 601665 607514

Related Diseases for Obesity

Diseases in the Obesity family:

Obesity, Mc4r-Related Obesity, Nr0b2-Related
Obesity, Pparg-Related Obesity, Ppargc1b-Related
Obesity, Pyy-Related Obesity, Sim1-Related
Obesity, Ucp3-Related

Diseases related to Obesity via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 722)
id Related Disease Score Top Affiliating Genes
1 obesity, nr0b2-related 33.1 ADRB2 MC4R
2 obesity, pparg-related 33.0 ADRB3 MC4R
3 obesity, sim1-related 33.0 ENPP1 MC4R
4 obesity, ucp3-related 33.0 GHRL MC4R
5 chagas disease 29.7 GHRL LEP MC4R
6 obesity, morbid, due to leptin receptor deficiency 12.1
7 obesity, adrenal insufficiency, and red hair due to pomc deficiency 12.1
8 mental retardation, truncal obesity, retinal dystrophy, and micropenis 12.1
9 obesity, morbid, due to leptin deficiency 12.1
10 morbid obesity and spermatogenic failure 12.1
11 retinal dystrophy and obesity 12.0
12 abdominal obesity-metabolic syndrome 3 12.0
13 morbid obesity 12.0
14 obesity with impaired prohormone processing 12.0
15 obesity, hyperphagia, and developmental delay 12.0
16 abdominal obesity-metabolic syndrome 1 11.9
17 mental retardation, epileptic seizures, hypogonadism and hypogenitalism, microcephaly, and obesity 11.9
18 abdominal obesity-metabolic syndrome 11.8
19 severe early-onset obesity-insulin resistance syndrome due to sh2b1 deficiency 11.7
20 obesity due to sim1 deficiency 11.7
21 momo syndrome 11.7
22 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 11.7
23 coloboma-obesity-hypogenitalism-mental retardation syndrome 11.7
24 aniridia - ptosis - intellectual disability - familial obesity 11.7
25 hydrocephalus obesity hypogonadism 11.7
26 cohen syndrome 11.6
27 obesity bmiq11 11.6
28 intellectual disability, epileptic seizures, hypogonadism and hypogenitalism, microcephaly, and obesity 11.6
29 obesity, ppargc1b-related 11.6
30 monogenic non-syndromic obesity, autosomal recessive 11.6
31 obesity bmiq12 11.6
32 obesity susceptibility, adrb2-related 11.6
33 mental retardation, obesity, mandibular prognathism, and eye and skin anomalies 11.6
34 obesity susceptibility, adrb3-related 11.6
35 obesity susceptibility, agrp-related 11.6
36 obesity susceptibility, enpp1-related 11.6
37 obesity susceptibility, ghrl-related 11.6
38 obesity, severe bmiq9 11.6
39 obesity due to congenital leptin deficiency 11.6
40 x-linked intellectual disability - short stature - obesity 11.6
41 obesity susceptibility, pomc-related 11.6
42 obesity bmiq4 11.6
43 obesity susceptibility, ucp1-related 11.6
44 congenital leptin deficiency 11.6
45 obesity bmiq18 11.6
46 intellectual disability-seizures-macrocephaly-obesity syndrome 11.6
47 obesity, pyy-related 11.6
48 intellectual disability-obesity-brain malformations-facial dysmorphism syndrome 11.6
49 short stature-brachydactyly-obesity-global developmental delay syndrome 11.6
50 obesity-colitis-hypothyroidism-cardiac hypertrophy-developmental delay syndrome 11.6

Graphical network of the top 20 diseases related to Obesity:



Diseases related to Obesity

Symptoms & Phenotypes for Obesity

Symptoms by clinical synopsis from OMIM:

601665

Clinical features from OMIM:

601665 607514

Human phenotypes related to Obesity:

56 32 (show all 10)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 obesity 56 32 Obligate (100%) HP:0001513
2 hypertension 56 32 Occasional (29-5%) HP:0000822
3 type ii diabetes mellitus 56 32 Occasional (29-5%) HP:0005978
4 hypertriglyceridemia 56 32 Occasional (29-5%) HP:0002155
5 acanthosis nigricans 56 32 Occasional (29-5%) HP:0000956
6 hyperinsulinemia 56 32 Occasional (29-5%) HP:0000842
7 polyphagia 56 32 Very frequent (99-80%) HP:0002591
8 increased adipose tissue 56 32 Obligate (100%) HP:0009126
9 childhood-onset truncal obesity 56 32 Frequent (79-30%) HP:0008915
10 decreased resting energy expenditure 32 HP:0012340

UMLS symptoms related to Obesity:


overweight, high weight, symptoms, obesity, metabolically benign, monogenic obesity

MGI Mouse Phenotypes related to Obesity:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.41 UCP3 ADRB2 ADRB3 AGRP CARTPT ENPP1
2 growth/size/body region MP:0005378 10.32 LEP MC4R NR0B2 POLG POMC PPARG
3 homeostasis/metabolism MP:0005376 10.32 ADRB2 ADRB3 AGRP CARTPT DDHD2 ENPP1
4 behavior/neurological MP:0005386 10.3 ADRB2 ADRB3 AGRP CARTPT DDHD2 ENPP1
5 endocrine/exocrine gland MP:0005379 10.14 FFAR4 GHRL LEP NR0B2 POLG POMC
6 cardiovascular system MP:0005385 10.09 ADRB2 ENPP1 GLDC LEP MC4R POLG
7 nervous system MP:0003631 9.93 ADRB2 AGRP DDHD2 ENPP1 FFAR4 GLDC
8 liver/biliary system MP:0005370 9.91 AGRP ENPP1 FFAR4 LEP MC4R NR0B2
9 no phenotypic analysis MP:0003012 9.5 ADRB2 AGRP MC4R POLG POMC PPARG
10 skeleton MP:0005390 9.28 ADRB2 CARTPT ENPP1 GLDC LEP MC4R

Drugs & Therapeutics for Obesity

Drugs for Obesity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 903)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
2
Acetaminophen Approved Phase 4,Phase 3,Phase 1 103-90-2 1983
3
Dalteparin Approved Phase 4 9041-08-1
4
Heparin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 9005-49-6 772 46507594
5
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 2 138402-11-6 3749
6 Moxonidine Approved Phase 4 75438-57-2 4810
7
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
8
Orlistat Approved, Investigational Phase 4,Phase 3,Phase 2 96829-58-2 3034010
9
Saxagliptin Approved Phase 4,Phase 2 361442-04-8 11243969
10
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
11
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
12
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
13
Letrozole Approved, Investigational Phase 4,Phase 3,Early Phase 1 112809-51-5 3902
14
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
15
Hydroxocobalamin Approved Phase 4,Phase 2,Phase 1,Early Phase 1 13422-51-0 11953898 5460373 44475014
16
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3 57-27-2 5288826
17 Nadroparin Approved Phase 4 9041-08-1
18
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Early Phase 1 50-23-7 5754 657311
19
Metyrapone Approved Phase 4 54-36-4 4174
20
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
21
Phentermine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 122-09-8 4771
22
Amlodipine Approved Phase 4,Phase 3,Phase 2 88150-42-9 2162
23
Losartan Approved Phase 4,Phase 3,Phase 1,Phase 2 114798-26-4 3961
24
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
25
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 2078-54-8 4943
26
Octreotide Approved, Investigational Phase 4,Phase 2 83150-76-9 383414 6400441
27
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2 144701-48-4 65999
28
Remifentanil Approved Phase 4,Phase 2,Phase 3 132875-61-7 60815
29
Rocuronium Approved Phase 4,Phase 2 119302-91-9, 143558-00-3 441290
30
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 141758-74-9 15991534
31
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 111025-46-8 4829
32
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
33
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1 97240-79-4 5284627
34
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
35
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
36
Olanzapine Approved, Investigational Phase 4,Phase 2,Phase 1 132539-06-1 4585
37
Menthol Approved Phase 4,Phase 2,Early Phase 1 2216-51-5 16666
38
Aripiprazole Approved, Investigational Phase 4,Phase 1 129722-12-9 60795
39
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1 106266-06-2 5073
40
Ziprasidone Approved Phase 4,Phase 1 146939-27-7 60854
41
Insulin Aspart Approved Phase 4,Phase 3,Phase 1 116094-23-6 16132418
42
Insulin Detemir Approved Phase 4,Phase 3 169148-63-4 5311023
43
Calcium carbonate Approved Phase 4,Phase 3,Phase 2 471-34-1
44
Ropivacaine Approved Phase 4,Early Phase 1 84057-95-4 71273 175805
45
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
46
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-82-4 7028
47
Glycerol Approved, Experimental Phase 4 56-81-5 753
48
Anastrozole Approved, Investigational Phase 4,Phase 3 120511-73-1 2187
49
Clozapine Approved Phase 4,Phase 1 5786-21-0 2818
50
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 437-38-7 3345

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Pharmacokinetics of Dexmedetomidine in Morbid Obesity Unknown status NCT01864187 Phase 4
2 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity Unknown status NCT01550601 Phase 4
3 Pharmacokinetics of Acetaminophen in Morbidly Obese Patients Unknown status NCT01764555 Phase 4
4 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
5 The Effect of Vitamin A Supplementation on Cytokine Profile in Obesity Unknown status NCT01405352 Phase 4
6 Anti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid Obesity Unknown status NCT01970202 Phase 4
7 The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension Unknown status NCT01360710 Phase 4
8 The Therapeutic Effect of Catgut Embedding in Obesity Unknown status NCT02276235 Phase 4
9 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4
10 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4
11 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4
12 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
13 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
14 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Unknown status NCT00288873 Phase 4
15 Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity Unknown status NCT00878592 Phase 4
16 Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4
17 Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4
18 Levonorgestrel-releasing Intrauterine Device on Obese Women: Effects on Hemostatic and Arterial Function Unknown status NCT01320917 Phase 4
19 CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug Unknown status NCT01519726 Phase 4
20 The Effects of Pentoxifylline on PAI-1 in an Obese Population Unknown status NCT00770328 Phase 4
21 Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men Unknown status NCT02097680 Phase 4
22 Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment Unknown status NCT01865448 Phase 4
23 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis Unknown status NCT01439425 Phase 4
24 Evaluation of a Family Intervention Program for the Management of Overweight or Obese Children Unknown status NCT01878994 Phase 4
25 Cardiovascular Effects of Metformin on Obesity Unknown status NCT01910246 Phase 4
26 Children's Healthy Living Program Unknown status NCT01881373 Phase 4
27 Vitamin Deficiencies and Suppletion in Morbid Obesity Unknown status NCT02270749 Phase 4
28 Mechanisms Underlying Postoperative Insulin Resistance and Inflammation Unknown status NCT01470534 Phase 4
29 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4
30 VAS Correlation With BMI Unknown status NCT02017314 Phase 4
31 Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
32 Prophylaxis of Venous Thromboembolism After Bariatric Surgery Unknown status NCT02295150 Phase 4
33 A Trial to Study the Effect of Long Term Vitamin D Supplementation on Insulin Sensitivity Unknown status NCT01052181 Phase 4
34 Clinical Study of Laparoscopic Non Banded Vertical Gastroplasty in Bariatric Surgery Unknown status NCT02050477 Phase 4
35 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
36 Cortisol and Nutritional Sympathetic Responsiveness Unknown status NCT01620684 Phase 4
37 Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia Unknown status NCT01805284 Phase 4
38 Physical Activity and ARTs Unknown status NCT01892111 Phase 4
39 Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
40 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4
41 Effect of Daily Glucomannan in Overweight Patients Unknown status NCT01485718 Phase 4
42 Studying the Effects of Phentermine on Eating Behavior Unknown status NCT01886937 Phase 4
43 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4
44 Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults Completed NCT02342418 Phase 4
45 Propofol Effect-Site Target Controlled Infusion in the Obese: Characterization of the Time Profile of Bispectral Index Response Completed NCT01665079 Phase 4
46 Enoxaparin Dosing in Obesity Completed NCT01798550 Phase 4
47 A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients Completed NCT00171613 Phase 4
48 Clinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity Completed NCT01639677 Phase 4
49 Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients Completed NCT03034941 Phase 4
50 Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes Completed NCT00847262 Phase 4

Search NIH Clinical Center for Obesity

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: obesity

Genetic Tests for Obesity

Genetic tests related to Obesity:

id Genetic test Affiliating Genes
1 Obesity 29 24
2 Body Mass Index Quantitative Trait Locus 10 29
3 Obesity, Autosomal Dominant 29

Anatomical Context for Obesity

MalaCards organs/tissues related to Obesity:

39
Liver, Ovary, Heart, Adipocyte, Skeletal Muscle, Bone, Breast

Publications for Obesity

Articles related to Obesity:

(show top 50) (show all 10451)
id Title Authors Year
1
Steatorrhea and Hyperoxaluria in Severely Obese Patients Before and After Roux-en-Y Gastric Bypass. ( 28089681 )
2017
2
Inhibition of the gut enzyme intestinal alkaline phosphatase may explain how aspartame promotes glucose intolerance and obesity in mice. ( 27997218 )
2017
3
Maternal obesity modulates intracellular lipid turnover in the human term placenta. ( 27780978 )
2017
4
Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome. ( 28525998 )
2017
5
Kidney disease and obesity: epidemiology, mechanisms and treatment. ( 28090083 )
2017
6
MAP4K4 and IL-6(+) Th17 cells play important roles in non-obese type 2 diabetes. ( 28061846 )
2017
7
Obesity and hypertension. ( 28532816 )
2017
8
Zinc Deficiency after Gastric Bypass for Morbid Obesity: a Systematic Review. ( 27885534 )
2017
9
Adenoma Detection Rates for Screening Colonoscopies in Smokers and Obese Adults: Data From the New Hampshire Colonoscopy Registry. ( 28059941 )
2017
10
Chronic insulin infusion induces reversible glucose intolerance in lean rats yet ameliorates glucose intolerance in obese rats. ( 27871838 )
2017
11
Acanthosis nigricans in obese adolescents: prevalence, impact, and management challenges. ( 28031729 )
2017
12
Portomesenteric vein thrombosis after laparoscopic sleeve gastrectomy for morbid obesity. ( 28069786 )
2017
13
Obesity and survival in critically ill patients with acute respiratory distress syndrome: a paradox within the paradox. ( 28532465 )
2017
14
Changes in muscle strength after diet-induced weight reduction in adult men with obesity: a prospective study. ( 28533692 )
2017
15
A novel role for the Wnt inhibitor APCDD1 in adipocyte differentiation: Implications for diet-induced obesity. ( 28242765 )
2017
16
Supervised Clustering of Adipokines and Hormonal Receptors Predict Prognosis in a Population of Obese Women with Type 1 Endometrial Cancer. ( 28505082 )
2017
17
Father's obesity programs the adipose tissue in the offspring via the local renin-angiotensin system and MAPKs pathways, especially in adult male mice. ( 28534168 )
2017
18
Influence of obesity on short- and long-term outcomes after laparoscopic distal gastrectomy for gastric cancer. ( 28534364 )
2017
19
Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor. ( 28373160 )
2017
20
Surgical Management of Obesity Among People with Schizophrenia and Bipolar Disorder: a Systematic Review of Outcomes and Recommendations for Future Research. ( 28508277 )
2017
21
Red meat and chicken consumption and its association with high blood pressure and obesity in South Korean children and adolescents: a cross-sectional analysis of KSHES, 2011-2015. ( 28532405 )
2017
22
Crosstalk between obesity and MMP-9 in cardiac remodelling -a cross-sectional study in apparent treatment-resistant hypertension. ( 27825280 )
2017
23
High free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independently of obesity and insulin resistance. ( 28487551 )
2017
24
Hypothalamic obesity after craniopharyngioma surgery: Treatment with a long acting glucagon like peptide 1 derivated. ( 28440760 )
2017
25
A Review of the Impact of Maternal Obesity on the Cognitive Function and Mental Health of the Offspring. ( 28534818 )
2017
26
Improving kidney disease in obese adolescents: a surgical approach. ( 28087009 )
2017
27
Intricate Evaluation of Association between Dental Caries and Obesity among the Children in Al-Kharj City (Saudi Arabia). ( 28050981 )
2017
28
The Impact of Peroxisome Proliferator-Activated Receptor Gamma and Its Interaction with Abdominal Obesity on Diabetic Nephropathy in Chinese Han. ( 28013303 )
2017
29
The new obesity-associated protein, neuronal growth regulator 1 (NEGR1), is implicated in Niemann-Pick disease Type C (NPC2)-mediated cholesterol trafficking. ( 27940359 )
2017
30
Laparoscopic Roux-en-Y gastric bypass versus laparoscopic mini gastric bypass in the treatment of obesity: study protocol for a randomized controlled trial. ( 28532499 )
2017
31
Obesity management: gastroenterologists take centre stage. ( 28532616 )
2017
32
Cardiovascular Events in Moderately to Severely Obese Obstructive Sleep Apnea Patients on Positive Airway Pressure Therapy. ( 28081532 )
2017
33
Paternal hyperglycemia in rats exacerbates the development of obesity in offspring. ( 28533422 )
2017
34
Obesity-linked phosphorylation of SIRT1 by CK2 inhibits its nuclear localization and promotes fatty liver. ( 28533219 )
2017
35
The FOXO1 Gene-Obesity Interaction Increases the Risk of Type 2 Diabetes Mellitus in a Chinese Han Population. ( 28049237 )
2017
36
Brown and White Adipose Tissue Expression of IL6, UCP1 and SIRT1 are Associated with Alterations in Clinical, Metabolic and Anthropometric Parameters in Obese Humans. ( 28073126 )
2017
37
The influence of gender and atopy in the relationship between obesity and asthma in childhood. ( 28126313 )
2017
38
Effects of octreotide on hepatic glycogenesis in rats with high fat dieta89induced obesity. ( 28534956 )
2017
39
Modification of the medical exclusion criterion in DSM-5 social anxiety disorder: Comorbid obesity as an example. ( 28064111 )
2017
40
The Relationship between Metabolic Parameters, Cardiac Parameters and MIC-1/GDF15 in Obese Children. ( 27750354 )
2017
41
Clinical Considerations of Silent Gastroesophageal Reflux Disease in Morbidly Obese Patients. ( 28452206 )
2017
42
Correlation of TLR4 and KLF7 in Inflammation Induced by Obesity. ( 27714571 )
2017
43
Role of Leptin and SOCS3 in Inhibiting the Type I Interferon Response During Obesity. ( 27704310 )
2017
44
The Adipokine Tartrate Resistant Acid Phosphatase 5a in Serum Correlates to Adipose Tissue Expansion in Obesity. ( 28532220 )
2017
45
Obesity-related genetic polymorphisms and adiposity indices in a young Italian population. ( 28090739 )
2017
46
Hispanic Patient Perspectives of the Physician's Role in Obesity Management. ( 28090233 )
2017
47
Using PaCO2 values to grade obesity-hypoventilation syndrome severity: a retrospective study. ( 28533903 )
2017
48
Optimal Pre-Pregnancy Body Mass Index Cut-Offs for Obesity in Japan. ( 28090236 )
2017
49
Royal jelly ameliorates diet-induced obesity and glucose intolerance by promoting brown adipose tissue thermogenesis in mice. ( 28089395 )
2017
50
Obesity and diabetes in 2017: a new year. ( 28091363 )
2017